Loading...
Market
What will be the EC's decision on Leqembi by March 31, 2025?
3
Resolution / Starting Odds
Approved without restrictions • 25%
Approved with restrictions • 25%
Rejected • 25%
Decision delayed • 25%
Official announcement from the European Commission
Story
EMA Recommends Leqembi for Early Alzheimer's in Patients with ApoE4 Gene; Biogen Shares Rise 5%
Nov 14, 2024, 04:16 PM
The European Medicines Agency (EMA) has recommended the approval of Leqembi, a drug developed by Eisai and Biogen, for the treatment of early Alzheimer's disease. This decision comes after the agency initially rejected the treatment months prior. The recommendation was made by the Committee for Medicinal Products for Human Use (CHMP) and pertains specifically to patients with one or no copies of the ApoE4 gene. The drug has been shown to slow cognitive decline in these patients. Following the announcement, Biogen's shares rose by as much as 5%. The final verdict from the European Commission is still pending.
View original story
Similar markets
Approval in another major market • 25%
Rejection in another major market • 25%
Reapplication in the EU • 25%
No major decision • 25%
Annulled • 25%
Upheld • 25%
Modified • 25%
Other • 25%
No significant irregularities found • 25%
Minor irregularities found • 25%
Major irregularities found • 25%
Election results invalidated • 25%
Ruling upheld • 25%
Ruling overturned • 25%
Settlement reached • 25%
Appeal withdrawn • 25%
United States • 25%
European Union • 25%
Russia • 25%
Other • 25%
Yes • 50%
No • 50%
IDF officials found guilty • 25%
IDF officials acquitted • 25%
Case dismissed • 25%
Other • 25%
Verdict Upheld • 25%
Verdict Overturned • 25%
Sentence Reduced • 25%
New Trial Ordered • 25%
Full compliance achieved • 25%
Partial compliance achieved • 25%
Non-compliance confirmed • 25%
Investigation extended • 25%
Improved compliance measures • 25%
Appeal against findings • 25%
Join anti-counterfeit group • 25%
No significant response • 25%